BPC-157, TB-500, GHK Basic, & KPV Blend
Also known as: KLOW Basic, KLOW (GHK Basic), Wolverine Basic
Available Suppliers & Pricing
Summary
BPC-157, TB-500, GHK Basic & KPV Blend has no established direct evidence for the exact multi-peptide combination. The defensible page should treat the blend as separate components with mostly preclinical research records. BPC-157 has rat tendon and tendon-to-bone data suggesting repair-related effects. TB-500 is commonly identified as the thymosin beta-4 fragment LKKTETQ, but stronger published evidence is for full-length thymosin beta-4 in wound-healing and angiogenesis models rather than for the commercial fragment itself. GHK or GHK-Cu research includes topical wound and connective-tissue remodeling studies. KPV has cell and mouse colitis data supporting anti-inflammatory mechanisms. None of these studies validates the combined blend.
Potential Benefits
Component Repair and Wound Models
BPC-157 tendon studies, full-length thymosin beta-4 wound-healing research, and GHK-Cu wound evidence support separate component-level repair biology contexts [1][2][3].
KPV Inflammation Models
KPV reduced inflammatory signaling and colitis severity in cell and mouse models [4].
Direct Blend Gap
No source evaluated the exact four-component blend, additive effects, dosing, or clinical usefulness.
Safety Information
FDA Component Cautions
FDA flags BPC-157, TB-500, KPV, and injectable GHK-Cu in the context of compounded bulk substances with significant safety concerns or insufficient human exposure data [5].
Multi-Peptide Uncertainty
Multi-peptide combinations can introduce interaction, impurity, and immune-response uncertainties not addressed by single-component studies.